Benefits
Complete muscle protein synthesis stimulation
Amino9® provides all nine EAAs in the ratios required for complete muscle protein synthesis — addressing the fundamental limitation of BCAA-only supplements that lack the full complement of amino acids needed to build new muscle proteins. No published trial has tested Amino9® itself. The supporting evidence is on generic EAA mixtures, and it is short-term and mechanistic: in an 8-subject crossover study in trained volunteers (Moberg 2016), a full EAA drink activated mTORC1 signalling more than leucine or BCAAs at 90 minutes after resistance exercise, but the advantage over BCAAs had disappeared by 180 minutes and the authors concluded the effect was 'primarily attributable to the BCAA'. These are signalling and synthesis-rate measurements over a few hours, not measured gains in muscle size or strength.
A more complete stimulus than BCAAs or leucine alone
Muscle protein synthesis requires all EAAs as substrates. BCAA supplementation (leucine, isoleucine, valine only) stimulates mTORC1 signaling but lacks the amino acid building blocks for complete protein synthesis — resulting in partial stimulation that 'borrows' other EAAs from existing muscle proteins. A complete EAA profile supplies those building blocks. This is a mechanistic argument, not a measured outcome: net protein accretion has never been measured for Amino9®, and while free-form EAAs are a more concentrated stimulus than protein gram for gram, no trial has shown that a complete EAA supplement produces more muscle than simply eating enough high-quality protein.
Use during caloric deficit - lean-mass preservation not demonstrated
EAAs supply an anabolic stimulus with almost no calories, which is why they are marketed for cutting phases and fasted training. The outcome data do not currently support the claim. In a randomized controlled trial of 68 Norwegian soldiers during 8 days of Arctic training in a roughly 24 percent energy deficit, EAA-dense supplemental bars did not change whole-body protein synthesis, breakdown or net balance compared with energy-dense or high-carbohydrate control bars, once protein intake was already above 1.6 g/kg/day (Howard 2026). A review by Gwin and colleagues similarly notes that supplemental whey protein during severe military energy deficit did not stimulate anabolic signalling or attenuate lean mass loss. Total daily protein intake, resistance training and the size of the deficit appear to matter far more than adding free-form EAAs on top.
Mechanism of action
Complete EAA delivery for maximal MPS
Muscle protein synthesis is rate-limited by the least abundant essential amino acid available (Liebig's Law of the Minimum applied to protein synthesis). Amino9® provides all nine EAAs, so no single EAA becomes limiting; the specific ratio, however, has never been shown superior to any other EAA ratio in a published comparison. Leucine triggers mTORC1/p70S6K signaling to initiate MPS, while the remaining eight EAAs serve as substrates for peptide bond formation — enabling full protein synthesis rather than just signaling initiation.
Clinical trials
No trial of the Amino9® blend exists. A PubMed search for Amino9[tiab] run on 2026-08-15 returned 14 records, all unrelated chemistry papers on amino-substituted anthraquinones and nucleosides dated 1978-2009; a search of '"Compound Solutions"[ad] OR "Compound Solutions"[tiab]' returned 59 records, none of them a trial of this ingredient. Compound Solutions' own Amino9® product page cites only third-party studies of generic leucine-enriched EAAs (Bukhari 2015; Wilkinson 2017/2018) and BCAAs (Jackman 2017) - none of which used Amino9®, and the page claims no patent. This card therefore summarises EAA-class evidence, not a study of the product.
Not applicable - no trial of Amino9® has been run, so there is no study population. The populations in the borrowed EAA research are: 14 healthy adults aged about 70 given 18 g EAA or 40 g balanced amino acids (Volpi 2003); 8 trained volunteers in a crossover signalling study (Moberg 2016); 24 women aged about 65 given 1.5 g or 6 g leucine-enriched EAA or 40 g whey (Wilkinson 2018); and 16 women aged about 66 given 3 g leucine-enriched EAA or 20 g whey (Bukhari 2015). None were resistance-trained adults taking Amino9®, and most were older women - a different population from the typical reader of this page.
Generic EAA mixtures do reliably raise muscle protein synthesis rates over the following 2-4 hours. What they have not done is beat protein food. In 24 older women (8 per arm), 1.5 g of leucine-enriched EAA, 6 g of the same EAA, and 40 g of whey raised muscle protein synthesis similarly, with what the authors called a negligible trophic advantage for the larger doses (Wilkinson 2018), and in 16 older women 3 g of leucine-enriched EAA matched 20 g of whey (Bukhari 2015). Volpi 2003 showed only that the essential fraction, not the non-essential amino acids, drives the response - not that EAAs beat protein. Longer-term outcomes such as muscle size, strength, power or time-trial performance have not been demonstrated for free-form EAA supplementation in healthy trained adults, and a 2025 scoping review of 80 trials in older adults concluded that protein and amino acid supplementation's effect on physical performance remains inconclusive. In energy deficit, an RCT of 68 soldiers found EAA-dense bars did not improve whole-body protein balance. Nothing in any of this is specific to Amino9®.